Last 22.70 INR
Change Today -0.25 / -1.09%
Volume 6.3K
PDI On Other Exchanges
Symbol
Exchange
PDI is not on other exchanges.
As of 6:06 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

parenteral drugs india ltd (PDI) Snapshot

Open
22.10
Previous Close
22.95
Day High
23.35
Day Low
22.10
52 Week High
01/3/14 - 45.00
52 Week Low
12/18/14 - 21.20
Market Cap
676.8M
Average Volume 10 Days
12.0K
EPS TTM
-41.69
Shares Outstanding
29.8M
EX-Date
09/13/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PARENTERAL DRUGS INDIA LTD (PDI)

Related News

No related news articles were found.

parenteral drugs india ltd (PDI) Related Businessweek News

No Related Businessweek News Found

parenteral drugs india ltd (PDI) Details

Parenteral Drugs (India) Limited operates as a healthcare company in India and internationally. It is involved in research, production, and manufacturing of pharmaceutical products, including intravenous infusion products, tablets, capsules, liquids syrups, injections, etc., as well as oncology and critical care products. The company was founded in 1983 and is based in Indore, India.

Founded in 1983

parenteral drugs india ltd (PDI) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 2.8M
Chief Executive and Whole-Time Director
Total Annual Compensation: 2.6M
Whole-Time Director
Total Annual Compensation: 1.4M
Compensation as of Fiscal Year 2014.

parenteral drugs india ltd (PDI) Key Developments

Parenteral Drugs (India) Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Parenteral Drugs (India) Limited reported unaudited standalone and consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 474.631 million, loss from operations before other income, finance costs and exceptional items of INR 16.968 million, loss from ordinary activities before tax of INR 163.761 million, net loss for the period of INR 172.950 million or INR 5.80 per diluted share against net sales/income from operations of INR 528.305 million, loss from operations before other income, finance costs and exceptional items of INR 4.792 million, loss from ordinary activities before tax of INR 137.411 million, net loss for the period of INR 141.411 million or INR 5.47 per diluted share a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 1,003.424 million, loss from operations before other income, finance costs and exceptional items of INR 41.453 million, loss from ordinary activities before tax of INR 330.349 million, net loss for the period of INR 348.727 million or INR 11.70 per diluted share against net sales/income from operations of INR 1,030.717 million, loss from operations before other income, finance costs and exceptional items of INR 16.831 million, loss from ordinary activities before tax of INR 278.685 million, net loss for the period of INR 291.185 million or INR 11.26 per diluted share a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 676.799 million, loss from operations before other income, finance costs and exceptional items of INR 26.091 million, loss from ordinary activities before tax of INR 198.677 million, net loss for the period of INR 205.566 million or INR 6.90 per diluted share against net sales/income from operations of INR 739.783 million, profit from operations before other income, finance costs and exceptional items of INR 21.361 million, loss from ordinary activities before tax of INR 133.227 million, net loss for the period of INR 137.277 million or INR 5.31 per diluted share a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 1,447.927 million, loss from operations before other income, finance costs and exceptional items of INR 55.509 million, loss from ordinary activities before tax of INR 392.335 million, net profit for the period of INR 410.711 million or INR 13.77 per diluted share against net sales/income from operations of INR 1,546.862 million, profit from operations before other income, finance costs and exceptional items of INR 25.623 million, profit from ordinary activities before tax of INR 251.915 million, net profit for the period of INR 370.727 million or INR 14.33 per diluted share a year ago.

Parenteral Drugs (India) Limited to Report Q2, 2015 Results on Nov 14, 2014

Parenteral Drugs (India) Limited announced that they will report Q2, 2015 results on Nov 14, 2014

Parenteral Drugs (India) Limited, Board Meeting, Nov 14, 2014

Parenteral Drugs (India) Limited, Board Meeting, Nov 14, 2014. Agenda: To consider unaudited financial results of the company for the quarter ended 30 September, 2014 and other items as per agenda of the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDI:IN 22.70 INR 0.00

PDI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDI.
View Industry Companies
 

Industry Analysis

PDI

Industry Average

Valuation PDI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARENTERAL DRUGS INDIA LTD, please visit www.pdindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.